Laguna Biotherapeutics

Executive Summary

Laguna Biotherapeutics is a San Diego-based private biotechnology company founded in 2018 that is developing next-generation cancer immunotherapies using engineered microbial platforms. The company's innovative approach focuses on activating powerful innate immune cells, specifically γδ T cells and MAIT cells, directly inside the body to overcome tumor immune evasion. By leveraging attenuated microbes as delivery vectors, Laguna aims to address refractory cancers that are resistant to current treatments, including checkpoint inhibitors and CAR-T therapies. The platform has the potential to induce potent antitumor immunity while minimizing systemic toxicity, offering a novel therapeutic modality for hard-to-treat malignancies. Despite being in early preclinical stages, Laguna's unique mechanism of action and focus on innate immunity differentiate it from conventional immuno-oncology approaches. The company has not disclosed its pipeline or financing history publicly, but its scientific foundation is supported by emerging research on the role of γδ T cells and MAIT cells in cancer immunity. Key near-term milestones are expected to include preclinical proof-of-concept data, advancement of a lead candidate toward IND-enabling studies, and potential capital raises to support development. If successful, Laguna could establish a new class of microbial-based immunotherapies with broad applicability across multiple solid tumors.

Upcoming Catalysts (preview)

• Q1 2027Preclinical efficacy data for lead microbial immunotherapy candidate55% success
• Q4 2026Series A or B financing round to advance pipeline65% success
• TBDIND filing for first candidate40% success